N/A
Manufactured by Pfizer Laboratories Div Pfizer Inc
15,699 FDA adverse event reports analyzed
Last updated: 2026-04-14
CRISABOROLE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Pfizer Laboratories Div Pfizer Inc. The most commonly reported adverse reactions for CRISABOROLE include DRUG INEFFECTIVE, APPLICATION SITE PAIN, BURNING SENSATION, OFF LABEL USE, CONDITION AGGRAVATED. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CRISABOROLE.
Out of 9,400 classified reports for CRISABOROLE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 15,699 FDA FAERS reports that mention CRISABOROLE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, APPLICATION SITE PAIN, BURNING SENSATION, OFF LABEL USE, CONDITION AGGRAVATED, PRURITUS. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Pfizer Laboratories Div Pfizer Inc in connection with CRISABOROLE. Always verify the specific product and NDC with your pharmacist.